publication . Other literature type . 2022

Development of prophylactic nucleic acid-based vaccine against SARS-CoV-2

Almansour, Iman;
en-EN
  • Published: 01 Jan 2022
  • Publisher: Federal Institute for Risk Assessment
Abstract
The newly emergent novel coronavirus nCoV-19, which was later named SARS-CoV-2, has been recently identified in Wuhan, China in 2019. As of 15th of February, a total of 73,335<br style="margin:0px;padding:0px;list-style: none;border:none;color: rgb(51, 51, 51);font-family: Arial, Helvetica, sans-serif;">cases had been reported globally with 1,873 reported deaths. Therefore, development of prophylactic vaccines against SARS-CoV-2 is a global priority. Currently, no licensed vaccines or therapeutics exist against SARS-CoV-2 or the other human<br style="margin:0px;padding:0px;list-style: none;border:none;color: rgb(51, 51, 51);font-family: Arial, Helvetica, sans-se...
Subjects
free text keywords: SARS-CoV-2, COVID-19, DNA Vaccine, Spike
Communities
COVID-19
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue